Agios Pharmaceuticals Inc (0HB0.L)

Name: Agios Pharmaceuticals Inc Financial Statements
Creator: Quarter Results

Healthcare | Medical Pharmaceuticals

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$20.0M

Net Income

-$108M

Operating Margin

-608.9%

Free Cash Flow

-$377M

Debt / Assets

8.0%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Agios Pharmaceuticals Inc (0HB0.L).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	19,967,000	12,880,000	12,455,000	8,726,000
Cost of Revenue	620,000	1,679,000	2,961,000	1,085,000
Gross Profit	19,347,000	11,201,000	9,494,000	7,641,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	51,610,000	41,274,000	45,869,000	41,527,000
Operating Expenses	140,925,000	128,070,000	136,550,000	114,270,000
Operating Income	-121,578,000	-116,869,000	-127,056,000	-106,629,000
Interest Expense	0	0	0	0
Income Before Tax	-109,055,000	-103,433,000	-112,020,000	-89,289,000
Income Tax Expense	-1,016,000	0	0	0
Net Income	-108,039,000	-103,433,000	-112,020,000	-89,289,000
Per Share
EPS	-1.85	-1.78	-1.93	-1.55
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Agios Pharmaceuticals Inc (0HB0.L).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	54,028,000	36,498,000	26,823,000	14,240,000
Cost of Revenue	6,345,000	4,165,000	9,504,000	20,263,000
Gross Profit	47,683,000	32,333,000	17,319,000	-6,023,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	180,280,000	156,784,000	119,903,000	111,678,000
Operating Expenses	519,815,000	458,070,000	408,806,000	383,024,000
Operating Income	-472,132,000	-425,737,000	-391,487,000	-389,047,000
Interest Expense	0	0	0	0
Income Before Tax	-413,797,000	717,969,000	-352,088,000	-231,801,000
Income Tax Expense	-1,016,000	44,244,000	0	0
Net Income	-412,781,000	673,725,000	-352,088,000	-231,801,000
Per Share
EPS	-7.12	11.86	-6.33	-4.23
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Agios Pharmaceuticals Inc (0HB0.L).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	89,130,000	76,247,000	88,205,000	139,259,000
Short Term Investments	765,295,000	817,463,000	688,723,000	643,860,000
Net Receivables	10,577,000	4,109,000	2,810,000	2,206,000
Inventory	32,920,000	27,616,000	19,076,000	8,492,000
Total Current Assets	942,052,000	965,600,000	833,835,000	832,772,000
Property Plant Equipment	41,229,000	54,554,000	69,791,000	88,116,000
Goodwill and Intangibles	0	0	0	0
Total Assets	1,297,225,000	1,663,199,000	937,118,000	1,238,718,000
Liabilities
Account Payables	18,355,000	16,643,000	9,780,000	18,616,000
Short Term Debt	18,392,000	16,781,000	15,008,000	13,663,000
Total Current Liabilities	82,206,000	81,156,000	67,955,000	62,629,000
Long Term Debt	43,630,000	40,207,000	56,988,000	0
Total Liabilities	104,111,000	122,243,000	126,099,000	137,904,000
Shareholders Equity
Retained Earnings	-561,705,000	-148,924,000	-822,649,000	-470,561,000
Total Shareholders Equity	1,193,114,000	1,540,956,000	811,019,000	1,100,814,000

Balance sheet annual history for Agios Pharmaceuticals Inc (0HB0.L).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	89,130,000	76,247,000	88,205,000	139,259,000
Short Term Investments	765,295,000	817,463,000	688,723,000	643,860,000
Net Receivables	10,577,000	4,109,000	2,810,000	2,206,000
Inventory	32,920,000	27,616,000	19,076,000	8,492,000
Total Current Assets	942,052,000	965,600,000	833,835,000	832,772,000
Property Plant Equipment	41,229,000	54,554,000	69,791,000	88,116,000
Goodwill and Intangibles	0	0	0	0
Total Assets	1,297,225,000	1,663,199,000	937,118,000	1,238,718,000
Liabilities
Account Payables	18,355,000	16,643,000	9,780,000	18,616,000
Short Term Debt	18,392,000	16,781,000	15,008,000	13,663,000
Total Current Liabilities	82,206,000	81,156,000	67,955,000	62,629,000
Long Term Debt	43,630,000	40,207,000	56,988,000	0
Total Liabilities	104,111,000	122,243,000	126,099,000	137,904,000
Shareholders Equity
Retained Earnings	-561,705,000	-148,924,000	-822,649,000	-470,561,000
Total Shareholders Equity	1,193,114,000	1,540,956,000	811,019,000	1,100,814,000

Cash flow quarterly history for Agios Pharmaceuticals Inc (0HB0.L).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-412,781,000	673,725,000	-352,088,000	-231,801,000
Depreciation & Amortization	5,177,000	5,653,000	6,623,000	18,559,000
Stock Based Compensation	52,552,000	42,847,000	44,766,000	49,296,000
Change in Working Capital	-33,042,000	-19,768,000	-19,057,000	-16,433,000
Operating Cash Flow	-372,977,000	-389,841,000	-296,062,000	-309,478,000
Investing Activities
Capital Expenditure	-4,316,000	-1,685,000	-999,000	-4,881,000
Investments	-4,316,000	-1,685,000	-999,000	-4,881,000
Investing Cash Flow	377,184,000	363,441,000	239,575,000	243,261,000
Financing Activities
Debt Repayment	0	0	0	-331,000
Common Stock Issued/Repurchased	8,676,000	14,442,000	5,433,000	2,681,000
Dividends Paid	0	0	0	0
Financing Cash Flow	8,676,000	14,442,000	5,433,000	2,350,000
Summary
Free Cash Flow	-377,293,000	-391,526,000	-297,061,000	-314,359,000
Net Change in Cash	12,883,000	-11,958,000	-51,054,000	-63,867,000

Cash flow annual history for Agios Pharmaceuticals Inc (0HB0.L).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-412,781,000	673,725,000	-352,088,000	-231,801,000
Depreciation & Amortization	5,177,000	5,653,000	6,623,000	18,559,000
Stock Based Compensation	52,552,000	42,847,000	44,766,000	49,296,000
Change in Working Capital	-33,042,000	-19,768,000	-19,057,000	-16,433,000
Operating Cash Flow	-372,977,000	-389,841,000	-296,062,000	-309,478,000
Investing Activities
Capital Expenditure	-4,316,000	-1,685,000	-999,000	-4,881,000
Investments	-4,316,000	-1,685,000	-999,000	-4,881,000
Investing Cash Flow	377,184,000	363,441,000	239,575,000	243,261,000
Financing Activities
Debt Repayment	0	0	0	-331,000
Common Stock Issued/Repurchased	8,676,000	14,442,000	5,433,000	2,681,000
Dividends Paid	0	0	0	0
Financing Cash Flow	8,676,000	14,442,000	5,433,000	2,350,000
Summary
Free Cash Flow	-377,293,000	-391,526,000	-297,061,000	-314,359,000
Net Change in Cash	12,883,000	-11,958,000	-51,054,000	-63,867,000